The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production

Transplant Immunology

Volumn 28, Issue 4, 2013, Pages 183-188

  Smeekens, Sanne P ^a   van den Hoogen, Martijn W F ^a   Kamburova, Elena G ^a   van de Veerdonk, Frank L ^a   Joosten, Irma ^a   Koenen, Hans J M P ^a   Netea, Mihai G ^a   Hilbrands, Luuk B ^a   Joosten, Leo A B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

B cell; Cytokines; Interleukin 17; Renal transplantation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 6; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOCYTE FUNCTION; MALE; MOLECULAR DYNAMICS; PATIENT ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MIDDLE AGED; TH17 CELL;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; KIDNEY TRANSPLANTATION; LIVING DONORS; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; TH17 CELLS;

EID: 84879843324     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.04.008     Document Type: Article

References (25)

1. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
2. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
3. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5:101-104.
4. van de Veerdonk F.L., Lauwerys B., Marijnissen R.J., Timmermans K., Di Padova F., Koenders M.I., et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011, 63:1507-1516.
5. van den Hoogen M.W., Hilbrands L.B. Use of monoclonal antibodies in renal transplantation. Immunotherapy 2011, 3:871-880.
6. Hauser I.A., Spiegler S., Kiss E., Gauer S., Sichler O., Scheuermann E.H., et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005, 16:1849-1858.
7. Hoffmann S.C., Hale D.A., Kleiner D.E., Mannon R.B., Kampen R.L., Jacobson L.M., et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005, 5:573-581.
8. Halloran P.F., Miller L.W., Urmson J., Ramassar V., Zhu L.F., Kneteman N.M., et al. IFN-gamma alters the pathology of graft rejection: protection from early necrosis. J Immunol 2001, 166:7072-7081.
9. Miura M., El-Sawy T., Fairchild R.L. Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma. Am J Pathol 2003, 162:509-519.
10. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
11. Agorogiannis E.I., Regateiro F.S., Howie D., Waldmann H., Cobbold S.P. Th17 cells induce a distinct graft rejection response that does not require IL-17A. Am J Transplant 2012, 12:835-845.
12. Antonysamy M.A., Fanslow W.C., Fu F., Li W., Qian S., Troutt A.B., et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999, 162:577-584.
13. Itoh S., Kimura N., Axtell R.C., Velotta J.B., Gong Y., Wang X., et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion. Circulation 2011, 124:S187-S196.
14. Loong C.C., Hsieh H.G., Lui W.Y., Chen A., Lin C.Y. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002, 197:322-332.
15. Van Kooten C., Boonstra J.G., Paape M.E., Fossiez F., Banchereau J., Lebecque S., et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998, 9:1526-1534.
16. van de Veerdonk F.L., Marijnissen R.J., Kullberg B.J., Koenen H.J., Cheng S.C., Joosten I., et al. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 2009, 5:329-340.
17. Lehrer R.I., Cline M.J. Interactions of Candida albicans with human leukocytes and serum. J Bacteriol 1969, 98:996-1004.
18. Agarwal A., Vieira C.A., Book B.K., Sidner R.A., Fineberg N.S., Pescovitz M.D. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004, 4:1357-1360.
19. Johansen P., Weiss A., Bunter A., Waeckerle-Men Y., Fettelschoss A., Odermatt B., et al. Clemastine causes immune suppression through inhibition of extracellular signal-regulated kinase-dependent proinflammatory cytokines. J Allergy Clin Immunol 2011, 128:1286-1294.
20. Furukawa Y., Yoshikawa H., Iwasa K., Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 2008, 195:108-115.
21. Smeekens S.P., van de Veerdonk F.L., van der Meer J.W., Kullberg B.J., Joosten L.A., Netea M.G. The Candida Th17 response is dependent on mannan- and {beta}-glucan-induced prostaglandin E2. Int Immunol 2010.
22. + T cells. Eur J Immunol 2009, 39:1301-1312.
23. Scales W.E., Chensue S.W., Otterness I., Kunkel S.L. Regulation of monokine gene expression: prostaglandin E2 suppresses tumor necrosis factor but not interleukin-1 alpha or beta-mRNA and cell-associated bioactivity. J Leukoc Biol 1989, 45:416-421.
24. Spatafora M., Chiappara G., D'Amico D., Volpes D., Melis M., Pace E., et al. Prostaglandin E2 down-regulates the expression of tumor necrosis alpha gene by human blood monocytes. Adv Prostaglandin Thromboxane Leukot Res 1991, 21B:521-524.
25. Takahashi H.K., Liu K., Wake H., Mori S., Zhang J., Liu R., et al. Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 2009, 331:656-670.